Superworth

Passage BIO EPS PASG

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$11.32
Latest quarter, Q2 FY26
−$2.44
Fiscal year 2025
−$14.35

Passage BIO's earnings per share was −$11.32 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$2.44.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$14.35n/a
FY2024−$21.28n/a
FY2023−$37.40n/a
FY2022−$50.20n/a
FY2021−$69.60n/a
FY2020−$61.60n/a
FY2019−$215.40n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$2.44n/a−$11.32
Q1 FY26−$2.36n/a−$11.84
Q4 FY25−$4.08n/a−$14.35
Q3 FY25−$2.44n/a−$14.31
Q2 FY25−$2.96n/a−$18.02
Q1 FY25−$4.87n/a−$20.15
Q4 FY24−$4.04n/a−$21.28
Q3 FY24−$6.15n/a−$23.44
Q2 FY24−$5.09n/a−$27.09
Q1 FY24−$6.00n/a−$30.80
Q4 FY23−$6.20n/a−$37.40
Q3 FY23−$9.80n/a−$41.20

Against its peers

Companies in Healthcare nearest Passage BIO's size, closest first, today.

CompanyEPS, 12 monthsGrowth
PASGPassage BIO−$11.32
NEPHNephros$0.16+33% a year
ATNMActinium Pharmaceuticals$0.36
APTAlpha Pro Tech$0.41+24% a year
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ICCCImmucell$0.08−58% a year
KEQUKewaunee Scientific$2.76−33% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Passage BIO

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.